Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12417564 | 0.81 | PLG (0.34) | ROCK2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL12417505 | 0.78 | GLP1R (0.33) | ROCK2 | |
| SCHEMBL12893030 | 0.78 | ROCK2 (0.45) | ROCK2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL16315596 | 0.71 | AKT1 (0.40) | — | |
| SCHEMBL19982268 | 0.68 | NMT2 (0.40) | ROCK2 | |
| SCHEMBL14921199 | 0.68 | ROCK2 (0.45) | ROCK2 | |
| SCHEMBL16328743 | 0.68 | OPRK1 (0.47) | ROCK2 | |
| SCHEMBL12892953 | 0.68 | ROCK2 (0.44) | ROCK2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26798857 | 0.67 | KIF11 (0.42) | — | |
| SCHEMBL9363327 | 0.66 | HPGDS (0.43) | ROCK2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172390-A1 | Protein-Proteophore Complexes | ASCENDIS PHARMA A/S (DK) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172390-A1 | Protein-Proteophore Complexes | PSMG3, PSME1, PSMD11 | ROCK2 3836/4885HRH1 3730/4885PLG 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.